Selecta Biosciences (NASDAQ:SELB) had its target price reduced by equities research analysts at Mizuho to $4.00 in a research report issued on Monday, February 4th, The Fly reports. The firm presently has a “buy” rating on the stock. Mizuho’s price objective indicates a potential upside of 87.79% from the company’s previous close.
Several other equities research analysts have also weighed in on SELB. Zacks Investment Research upgraded Selecta Biosciences from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a report on Thursday, November 15th. UBS Group set a $6.00 target price on Selecta Biosciences and gave the company a “hold” rating in a research note on Friday, November 9th. ValuEngine lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Stifel Nicolaus restated a “buy” rating on shares of Selecta Biosciences in a research note on Tuesday, October 23rd. Finally, Needham & Company LLC cut their target price on Selecta Biosciences to $12.00 and set a “buy” rating for the company in a research note on Monday, January 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $15.46.
Shares of NASDAQ SELB traded up $0.14 during trading hours on Monday, hitting $2.13. The stock had a trading volume of 179,509 shares, compared to its average volume of 468,884. Selecta Biosciences has a 52 week low of $1.41 and a 52 week high of $16.55. The stock has a market cap of $47.86 million, a price-to-earnings ratio of -0.67 and a beta of 1.39.
In other news, Director Amir Nashat purchased 1,166,666 shares of the stock in a transaction on Friday, January 25th. The shares were acquired at an average price of $1.50 per share, for a total transaction of $1,749,999.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 25.20% of the company’s stock.
Large investors have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Selecta Biosciences by 40.4% during the second quarter. BlackRock Inc. now owns 884,564 shares of the company’s stock valued at $11,721,000 after purchasing an additional 254,586 shares in the last quarter. Fosun International Ltd acquired a new stake in Selecta Biosciences in the 4th quarter valued at about $531,000. Man Group plc grew its stake in Selecta Biosciences by 139.1% in the 3rd quarter. Man Group plc now owns 257,315 shares of the company’s stock valued at $4,001,000 after acquiring an additional 149,685 shares during the last quarter. Millennium Management LLC acquired a new stake in Selecta Biosciences in the 2nd quarter valued at about $1,583,000. Finally, Two Sigma Investments LP grew its stake in Selecta Biosciences by 87.8% in the 4th quarter. Two Sigma Investments LP now owns 200,498 shares of the company’s stock valued at $533,000 after acquiring an additional 93,719 shares during the last quarter. 51.45% of the stock is currently owned by hedge funds and other institutional investors.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.